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Abstract
Background: Triptans, 5-HT1B/ID agonists, act on peripheral and/or central terminals of trigeminal
ganglion neurons (TGNs) and inhibit the release of neurotransmitters to second-order neurons,
which is considered as one of key mechanisms for pain relief by triptans as antimigraine drugs.
Although high-voltage activated (HVA) Ca2+  channels contribute to the release of
neurotransmitters from TGNs, electrical actions of triptans on the HVA Ca2+ channels are not yet
documented.
Results: In the present study, actions of zolmitriptan, one of triptans, were examined on the HVA
Ca2+ channels in acutely dissociated rat TGNs, by using whole-cell patch recording of Ba2+ currents
(IBa) passing through Ca2+ channels. Zolmitriptan (0.1–100 μM) reduced the size of IBa in a
concentration-dependent manner. This zolmitriptan-induced inhibitory action was blocked by
GR127935, a 5-HT1B/1D antagonist, and by overnight pretreatment with pertussis toxin (PTX). P/
Q-type Ca2+ channel blockers inhibited the inhibitory action of zolmitriptan on IBa, compared to N-
and L-type blockers, and R-type blocker did, compared to L-type blocker, respectively (p < 0.05).
All of the present results indicated that zolmitriptan inhibited HVA P/Q- and possibly R-type
channels by activating the 5-HT1B/1D receptor linked to Gi/o pathway.
Conclusion: It is concluded that this zolmitriptan inhibition of HVA Ca2+ channels may explain the
reduction in the release of neurotransmitters including CGRP, possibly leading to antimigraine
effects of zolmitriptan.
Background
It is known that the pain associated with migraine is
relieved by triptans, 5HT1B/1D  agonists, including
sumatriptan, zolmitriptan, naratriptan and so on. Indeed,
they are in clinical use for treatment of migraine. It is
shown that trigeminal ganglion stimulation leads to the
release of CGRP in humans and cats, which is antagonized
by sumatriptan administration [1]. Subsequently, several
lines of histochemical and electrophysiological studies
demonstrate the involvement of 5HT1B/1D agonist in neu-
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Inhibition of HVA IBa by zolmitriptan Figure 1
Inhibition of HVA IBa by zolmitriptan. (a) Typical illustration of IBa elicited in response to command pulses from -60 mV to 
10 mV for 40 ms. IBa was inhibited by 2 min application of 10 μM zolmitriptan. (b) The average time course of IBa inhibition by 
zolmitriptan at four different concentrations. Superfusing application of zolmitriptan started at t = 0 and lasted for 120 s during 
the period indicated by horizontal bar. Mean value of the relative amplitude of IBa compared to the control IBa at t = 0 was plot-
ted on ordinate (IBa ratio) against time on abscissa. The number of neurons examined is indicated for the respective concentra-
tions. S.E.M. value was not indicated. (c) Concentration-inhibition relationship for zolmitriptan. Bar graph shows the relative 
amplitude of IBa at two minutes after application of zolmitriptan compared to the control. (*p < 0.05 **p < 0.01).
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GR127935 modulation on zolmitriptan-sensitive IBa Figure 2
GR127935 modulation on zolmitriptan-sensitive IBa. (a) GR127935, 5HT1B/1D antagonist, depressed the inhibition of IBa 
by zolmitriptan (10 μM). Bar graph shows that the zolmitriptan-induced inhibition of IBa was significantly reduced by pretreat-
ment with 0.3 μM of the antagonist GR127935 (*p < 0.05). IBa ratio is the value that IBa (test) was divided by IBa (control). Inset 
shows the time course of GR127935 and zolmitriptan application. IBa (control) and IBa (test) were recorded as shown in the 
chart. (b) Typical illustration of IBa in control (left), in the presence of 0.3 μM GR127935 (center), and 10 μM zolmitriptan 
added on 0.3 μM GR127935 (right).
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rotransmitter release from trigeminal ganglion neurons
(TGNs). First, 5HT1B and/or 1D receptors are localized in
trigeminal vascular systems [2]. 5HT1B receptors are dem-
onstrated on dural arteries [2] and 5HT1D receptors on
trigeminal sensory neurons including peripheral and cen-
tral projections [2-4]. Second, small and medium- sized
TGNs possess 5HT1B/1D receptors, colocalized with CGRP
and Substance P [5]. Third, naratriptan inhibits neuronal
activity in TGNs [6]. Fourth, synaptic transmission from
TGNs to central trigeminovascular neurons is blocked by
activation of presynaptic 5HT1B/1D receptors on central ter-
minals of meningeal nociceptors [7]. All of these studies
suggest that triptans might act on 5HT1B/1D receptors of
TGNs and inhibit the release of neurotransmitters such as
CGRP, reducing central and/or peripheral neuronal excit-
ability.
An activation of high-voltage activated (HVA) Ca2+ chan-
nels is known to trigger the release of neurotransmitters
and to control numerous neuronal functions such as neu-
ronal excitability. HVA Ca2+ channels are divided into four
subtypes; that is N-, P/Q-, L-, and R-type channels. All of
four subtypes of HVA Ca2+ channels are demonstrated to
be expressed in TGNs [8]. Recent findings indicate that the
blockade of HVA Ca2+ channels prevents CGRP release
and prevents dural vessel dilation, and so HVA Ca2+ block-
ade might minimize neurological inflammation [9].
Although it is shown that N- and P/Q-currents are inhib-
ited via G protein-coupled mechanisms by agonists for
5HT1A and 1D receptors in the primary spinal neurons of
Xenopus larvae [10,11], effects of 5HT1B/!D agonists on
HVA Ca2+ channels in mammalian TGNs have not yet
been evaluated.
As mentioned above, involvement of triptans in modula-
tion of CGRP release as well as neuronal activity in the
trigeminal ganglion is highly plausible. This prompted us
to examine whether or not triptans could act on HVA Ca2+
channels of TGNs, leading to inhibition of the release of
CGRP and neurotransmission, possibly involved in gener-
ation of migraine. In the present study, electrophysiologi-
cal experiments were undertaken to analyze actions of
zolmitriptan, one of triptans, on HVA Ca2+ channels using
cultured neonatal rat TGNs. This paper clarified that zol-
mitriptan could inhibit HVA Ca2+ channels by activating
5HT1B/1D receptor coupled to Gi/o pathway.
Results
Currents carried by Ba2+ passing through HVA Ca2+ chan-
nels, IBa, were recorded from somata of neonatal rat TGNs,
small to medium size of 22 to 27 μm in diameter. The
peak amplitude of IBa in control varied within the range
from 230 to 1200 pA (mean ± S.E.M.; 508.5 ± 31.0 pA, n
= 37).
Concentration-dependent action of zolmitriptan on IBa
Zolmitriptan was applied to TGNs by superfusion for two
minutes. As shown in Fig. 1a, IBa was inhibited in the pres-
ence of zolmitriptan at 10 μM. Inhibitory actions of zol-
mitriptan on IBa were examined at concentrations between
0.1 and 100 μM (Fig. 1b, the number of cells indicated).
Zolmitriptan at lower concentrations slowly started
depressing the IBa at 10 to 20 s from the onset of applica-
tion. This depressing action slowly increased but could
not reach its maximum in 2 min at concentrations lower
than 10 μM. On the other hand, at 100 μM, the IBa was
very rapidly inhibited within 10 s and completely abol-
ished within one min of the drug application.
As noticed from Fig. 1b, this inhibitory effect of zol-
mitriptan on IBa lasted after the end of the drug applica-
tion and afterwards became more marked, attaining to its
peak. Then, it should be noted that the inhibitory action
of zolmitriptan on IBa could be hardly washed out. There-
fore, the inhibitory effect of the drug was compared by
using the IBa ratio (see Method and figure legend) at 2 min
after the onset of the application. The IBa ratios were 0.96
± 0.06 (0.1 μM, n = 4), 0.81 ± 0.08 (1 μM, n = 6), 0.75 ±
0.07 (5 μM, n = 6), 0.71 ± 0.06 (10 μM, n = 12), 0.40 ±
0.12 (40 μM, n = 8), and 0.00 ± 0.00 (100 μM, n = 3), and
compared with the IBa ratio of control group without zol-
mitriptan (0.97 ± 0.03, n = 3), as summarised in Fig. 1c,
showing the concentration-inhibition relationship for the
action of zolmitriptan on IBa.
Action of zolmitriptan, inhibited by a 5HT1B/1D antagonist
Since triptans are known to act as 5-HT1B/1D agonists, we
examined whether or not the zolmitriptan-induced inhi-
bition on IBa could be blocked by a 5-HT1B/1D receptor
antagonist, GR127935. The preparations were pretreated
with GR127935 for 2 min; no direct actions of the antag-
onist on IBa  were observed at 0.3 μM. Following
GR127935 application for more than 2 min, zolmitriptan
(5 and 10 μM) was added to the superfusate. The IBa ratios
with 10 μM zolmitriptan were 0.71 ± 0.06 (without
GR127935, n = 12), 0.72 ± 0.10 (0.1 μM GR127935, n =
6), 1.10 ± 0.04 (0.3 μM GR127935, n = 4), as summarized
in Fig. 2. It was shown that the zolmitriptan-induced inhi-
bition of IBa was significantly reduced by GR127935 at 0.3
μM. On the other hand, the IBa ratios with 5 μM zol-
mitriptan were 0.75 ± 0.07 (without GR127935, n = 6),
0.84 ± 0.13 (0.1 μM GR127935, n = 4), showing no signif-
icant inhibition. These data suggested that zolmitriptan
inhibited IBa by activating 5-HT1B/1D receptors. It should
be added that GR127935 at concentrations higher than 1
μM occasionally inhibited IBa.
Action of zolmitriptan, mediated by G-protein pathway
It is widely accepted that some of 5-HT receptor subtypes
are G-protein coupled. Possible involvement of G-proteinMolecular Pain 2006, 2:10 http://www.molecularpain.com/content/2/1/10
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pathways in the present action of zolimitriptan was tested
by using pertussis toxin (PTX, an irreversible inhibitor of
Gi/o proteins). When cultured TGNs were treated over-
night with PTX (500 ng/ml), zolmitriptan at 10 μM could
not exert an inhibitory effect on IBa; the amplitude of IBa in
control was almost the same as that of IBa in the presence
of zolmitriptan; that is IBa ratio = 1.0 as shown in Fig. 3.
Thus, PTX pretreatment prevented the inhibition of IBa by
zolmitriptan, while IBa  was depressed by zolmitriptan
without the PTX pretreatment. This significant change
induced by PTX indicated the role of G-proteins in the zol-
mitriptan inhibition of IBa.
Pharmacological profile of IBa, sensitive to zolmitriptan
Characteristics of IBa inhibited by zolmitriptan were phar-
macologically determined by using a variety of selective
Ca2+ channel blockers. Indeed, four types of HVA Ca2+
channels are known to be expressed in TGNs; that is, N-
type, P/Q-type, R-type, and L-type channels. In the present
experiments, therefore, ω-conotoxin GVIA (ω-CgTx, 1
μM), ω-agatoxin IVA (ω-Aga, 0.2 μM), SNX-482 (0.1 μM),
and nicardipine (10 μM) were used to examine possible
contribution of each Ca2+ channel to the zolmitriptan-
sensitive IBa, respectively. It is confirmed that all four Ca2+
blockers reduced IBa; ratios of IBa in the presence of Ca2+
blockers to control IBa were 0.42 ± 0.05 (ω-CgTx, n = 5);
0.58 ± 0.04 (ω-Aga, n = 4); 0.84 ± 0.05 (SNX-482, n = 7);
and 0.43 ± 0.08 (nicardipine, n = 4).
After pretreatment with each of blockers for 2 min, zol-
mitriptan (10 μM) was added to the superfusing solu-
tions, and IBa ratios were obtained (see inset of Fig. 4).
When pretreated with ω-CgTx, the IBa ratio was 0.55 ± 0.02
(n = 5); with ω-Aga, 0.89 ± 0.05 (n = 4); with SNX-482,
0.80 ± 0.03 (n = 7); and with nicardipine, 0.28 ± 0.15 (n
= 4) (Fig. 4). The IBa ratios after pretreatment with ω-Aga
or SNX-482 seemed to be larger than the ratio 0.71 ± 0.06
(10 μM zolmitriptan without Ca2+ blockers) in Fig. 1c,
suggesting a possibility that Ca2+ channels sensitive to ω-
Aga or SNX-482 likely contributed to the blockade of zol-
mitriptan IBa inhibition. Indeed, significant difference was
detected between ω-Aga and ω-CgTx or nicardipine, and
also between SNX-482 and nicardipine (Fig. 4), indicating
that blockade of P/Q-type and R-type Ca2+ channels with
ω-Aga and SNX-482 reduced the inhibition of IBa by zol-
mitriptan. Therefore, it is likely that P/Q-type and R-type
channels could be inhibited by zolmitriptan by acting on
5-HT1B/1D receptors through G proteins pathways.
Discussion
The present experiments demonstrated modulating
actions by zolmitriptan on IBa of the rat isolated TGNs.
Zolmitriptan inhibited HVA Ca2+ currents carried by Ba2+
in a concentration-dependent manner within the concen-
tration range between 0.1 μM and 100 μM by acting on
5HT1B/1D receptor through Gi/o protein-coupled pathway.
5HT receptors are divided into 7 families, 5HT1~7 recep-
tors, on the basis of their amino acid sequences and other
properties. 5HT1 receptors are further subdivided accord-
ing to their physiological functions, binding affinity and
other features [12]. The present study showed that
GR127935, a potent 5HT1B/1D receptor antagonist abol-
ished the effect of zolmitriptan, meaning that zol-
mitriptan acted on 5HT1B/1D receptor.
5HT1B and/or 1D subtypes are known as G-protein medi-
ated receptors. In the present study, pretreatment with
PTX inhibited the IBa inhibition by zolmitriptan, indicat-
ing the involvement of Gi/o protein coupled pathway. This
observation might be compatible with the previous
reports that an increase in intracellular Ca2+ level by 5HT1
receptor is associated with activation of Gi/Go protein cou-
pled pathway [13,14] and that the modulation of neuro-
nal voltage-gated Ca2+ channel is mediated by receptors
coupled to PTX-sensitive G proteins [15,16]. In this con-
text, possible involvement of stimulatory of G-proteins
(Gs) in the zolmitriptan action should be further investi-
gated by using cholera toxin. A recent report shows that
sumatriptan could activate the other second messenger
MAPK pathway leading to changes in intracellular Ca2+
changes [17]. This possibility for the action of zol-
mitriptan remains to be considered in future.
PTX modulation on zolmitriptan-sensitive IBa Figure 3
PTX modulation on zolmitriptan-sensitive IBa. PTX 
treatment prevented the inhibition of IBa by zolmitriptan (10 
μM). Bar graph shows that the zolmitriptan-induced inhibi-
tion of IBa was significantly reduced by overnight treatment of 
500 ng/ml PTX (*p < 0.05). Recording of IBa (control) and IBa 
(test) in the presence of zolmitriptan were made according 
to the same time course shown in the inset of figure 2. IBa 
ratio means IBa (test)/IBa (control).
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It is reported that triptans, antimigraine drugs might
inhibit the release of vasoactive neuropeptide from
trigeminovascular nerve endings and also inhibit trans-
mission of nociceptive impulses to second-order neurons
of the trigeminocervical complex, resulting in the antimi-
graine effect of triptan [18]. It is known that the trigeminal
ganglion possesses small to medium size 5HT1B/1D recep-
tor positive peptidergic neurons [4,5] and furthermore
that antimigraine drugs could block synaptic transmission
between meningeal nociceptors and central trigeminal
Pharmacological characteristics of zolmitriptan-sensitive IBa Figure 4
Pharmacological characteristics of zolmitriptan-sensitive IBa. Bar graph shows that inhibition of IBa was significantly 
reduced with ω-Aga, compared to those with ω-CgTx and nicardipine, Aand with SNX-482, compared to that with nicardipine 
(*p < 0.05). IBa (control) after pretreatment with Ca2+ blockers and IBa (test) 2 min after adding zolmitriptan were recorded as 
indicated in the inset. IBa ratio was obtained by IBa (test)/IBa (control).
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neurons presynaptically [7]. All of these suggest that HVA
Ca2+  channels, highly responsible to neurotransmitter
release from presynaptic terminal, might be involved in
the antimigraine effects of triptans. Indeed the present
study showed that HVA IBa of TGNs was affected by zol-
mitriptan, a 5HT1B/1D  agonist, strongly advocating the
idea that triptans inhibited neurotransmitter release from
peripheral or central presynaptic terminal through HVA
Ca2+ channels.
It is important to determine which subtypes of HVA Ca2+
channels might essentially contribute to the release of dif-
ferent neurotransmitters from various classes of neurons.
Some paper mentioned simply about HVA Ca2+ subtype
on trigeminal neurons, but there is no consensus about
which subtypes mainly contribute yet. Ebersberger et al
shows that discharge patterns of trigeminal second order
neurons with dural input are different in the presence of
each HVA Ca2+ subtype blockade [19], On the other hand,
Hong et al showed that N- and P/Q-channels are impor-
tant for the release of CGRP from perivascular TGNs [20]
and the release of CGRP is shown to be prevented when
N-, P/Q- or L- channels are blocked on trigeminal vascular
neuron [9]. The present study demonstrated that the inhi-
bition of zolmitriptan-sensitive IBa  in small-medium
TGNs depended mainly on activation of P/Q- and R-type
channels.
P/Q-type Ca2+ channels are reported to locate in all brain
structure [18] and also in the trigeminal ganglia [8]. Fur-
thermore,  α-eudesmol, a P/Q-type channel blocker,
inhibits the release of a neuropeptide from perivascular
trigeminal sensory nerves [21]. These observations may
support our present findings that P/Q-type channels
might be possible sites on which zolmitriptan could act in
cultured neonatal rat TGNs. Although N-type is also
known to locate in DRG neurons [22-24], a few studies
show the N-type channel dominance in TGNs. The
present study with ω-CgTx also could not statistically
demonstrate an appreciable involvement of N-type chan-
nels in the inhibition of zolmitriptan-sensitive IBa of cul-
tured rat TGNs.
R-type Ca2+ channels are shown to locate presynaptically
in the central nervous system, but the transmitter release
mediated by R-type channels is less efficient than that by
P/Q-and N-type channels [25]. In the process of develop-
ment, R-type channels are replaced by P/Q-type ones in
the central synaptic transmission [26]. There are similar
results for Ca2+ channel subtypes obtained from neonatal
and adult TGNs; in neonatal 4% are provided with P/Q-
type while 15% with R-type one [8]; in adult 40% with P/
Q-type while 5% to R-type [27]. In this context, the
present study, for the first time, demonstrated possible
involvement of R- as well as P/Q-type channels in the
actions of zolmitriptan on the cultured neonatal rat TGNs.
Although zolmitriptan (0.1~100 μM) inhibited IBa of cul-
tured TGNs, it is difficult to determine the effective con-
centration of zolmitriptan acting in vivo on the trigeminal
ganglion. Sumatriptan is reported to induce discharges in
dural primary afferent neurons at concentrations between
0.24 and 24 μM [28] and also cause vasocontraction in rat
isolated vena portae smooth muscle at concentrations
between 0.001 and 10 μM [29]; these indicate that actions
of two triptans could be exerted at similar concentrations.
Conclusion
Zolmitriptan inhibited IBa in a concentration-dependent
manner by acting on 5HT1B/1D receptor. P/Q- and possibly
R-type calcium channels contributed to the inhibition of
IBa by zolmitriptan. Gi/o protein pathway were involved.
Although this action of zolmitriptan on HVA Ca2+ chan-
nels might explain the antimigraine effect, more detailed
research of second messenger pathway would reveal the
further mechanism leading to antinociceptive effect of
triptans and pain pathway of migraine.
Method
Animal preparation
All procedures were carried out in accordance with the
guidelines for Animal Experimentation in Tokyo Medical
and Dental University (No.0060010). Wistar rats (0–7
days after birth, Saitama Experimental Animals Supply
Inc., Japan) were anesthetized by pentobarbital (i.p.).
After the decapitation of the rats, trigeminal ganglia were
dissected and treated with papain (20.3 units/ml) in low-
Ca2+ and low-Mg2+ Krebs' solution for 30 min at 37°C,
washed with modified Krebs' solution and triturated
using fire-polished Pasteur pipettes. Neurons were plated
onto poly-L-lysine pretreated 35 mm dishes. The plating
medium contained Dulbecco's modified Eagle's medium
with10% calf serum. The TGNs were kept in culture in
modified Krebs' solution saturated with 5% CO2 at 37°C
for 2 hours to one day before experiment. The ionic com-
position of the modified Krebs' solution was (mM): NaCl,
117; KCl, 4.7; CaCl2, 2.5; MgCl2, 1; glucose, 11; 3-(N-mor-
pholino) propanesulfonic acid (MOPS), 25; and pH 7.2
adjusted with NaOH. The low-Ca2+ and low-Mg2+ Krebs'
solution was made by adding EDTA (2.5 mM) to the mod-
ified Krebs' solution.
Electrophysiological recording
Membrane currents were recorded from somata of cul-
tured TGNs in the whole-cell voltage clamp configuration
of patch clamp technique with an Axopatch 1D amplifier
(Axon Instrument). Currents were filtered low-pass at 2
Hz by the built-in Bessel filter, and recorded on a chart
recorder (San-ei) for later analysis. Patch pipettes wereMolecular Pain 2006, 2:10 http://www.molecularpain.com/content/2/1/10
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pulled from borosilicate glass capillaries (Harvard) using
a puller (Narishige co.), and had input resistance of 5–10
MΩ after polishing. The ionic composition of the patch
pipette solution was (mM): CsCl, 100; MOPS, 40; MgCl2,
1; EGTA, 10; CaCl2, 1; ATP, 2 and pH 7.2 adjusted with
KOH. A series resistance of the recording system was not
electrically compensated.
Currents carried by Ba2+ passing through HVA Ca2+ chan-
nels, IBa, were evoked by depolarizing voltage step com-
mand pulse to +10 mV for 40 ms from a holding potential
of -60 mV every 10 s. For isolating Ba2+ currents an exter-
nal solution was used, containing (mM): TEA-Cl 140;
CsCl, 2.5; BaCl2, 2.5; MgCl2, 1; Glu, 11; HEPES, 10 and
pH 7.3 adjusted with TEA-OH. The amplitude of IBa was
determined as the difference between the baseline and the
peak inward current during each command pulse.
External solutions were applied continuously via a poly-
ethylene tube mounted on a micromanipulator and the
tip of the tube was positioned within 10 mm of the
recorded neurons. External solution was kept at 37°C.The
capacity of chamber was 150 μl and the flow rate of solu-
tion was 2 ml/min.
Materials
Zolmitriptan was a gift from Astrazeneca. Zolmitriptan
was dissolved in dimethylsulfoxide (DMSO) and stored at
-20°C. More dilute solutions were made daily dissolved
in external solution before every experiment. ω-CgTx, ω-
Aga and SNX-482 were purchased from Peptide Institute.
Nicardipine was from Sigma. GR127935 was from Tocris.
Data analysis
All data are expressed as means ± S.E.M. IBa ratio of Fig. 1b
was expressed as the relative amplitude in response to
each step command pulse compared to control values,
and IBa ratios shown in Fig 1c, 2, 3, 4 were expressed as the
relative amplitude after 120 s zolmitriptan application
compared to control values in the absence of zol-
mitriptan. Statistical significance was assessed with Stu-
dent's t-test for simple comparisons and Bonferroni-type
multiple t-test for multiple comparison. Differences of P <
0.05 were considered to be significant.
List of Abbreviation
TGN, trigeminal ganglion neuron; HVA, high-voltage acti-
vated; IBa, Ba2+ currents; CGRP, calcitonin gene-related
peptide; PTX, pertussis toxin; ω-Aga, ω-agatoxin IVA; ω-
CgTx, ω-conotoxin GVIA; DRG, dorsal root ganglion; i.p.,
intraperitoneally; MOPs, 3-(N-morpholino) propanesul-
fonic acid; EDTA, ethylenediaminetetraacetic acid; EGTA,
ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-
tetraacetic acid; HEPES, 2-[4-(2-Hydroxyethyl)-1-piperad-
inyl] ethansulfonic acid; DMSO, dimethylsulfoxide.
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